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Abstract
Hemorrhagic shock is a leading cause of death in trauma patients
worldwide. Bleeding control, maintenance of tissue oxygenation
with fluid resuscitation, coagulation support, and maintenance of
normothermia remain mainstays of therapy for patients with
hemorrhagic shock. Although now widely practised as standard in
the USA and Europe, shock resuscitation strategies involving
blood replacement and fluid volume loading to regain tissue
perfusion and oxygenation vary between trauma centers; the
primary cause of this is the scarcity of published evidence and lack
of randomized controlled clinical trials. Despite enormous efforts to
improve outcomes after severe hemorrhage, novel strategies
based on experimental data have not resulted in profound changes
in treatment philosophy. Recent clinical and experimental studies
indicated the important influences of sex and genetics on
pathophysiological mechanisms after hemorrhage. Those findings
might provide one explanation why several promising experimental
approaches have failed in the clinical arena. In this respect, more
clinically relevant animal models should be used to investigate
pathophysiology and novel treatment approaches. This review
points out new therapeutic strategies, namely immunomodulation,
cardiovascular maintenance, small volume resuscitation, and so on,
that have been introduced in clinics or are in the process of being
transferred from bench to bedside. Control of hemorrhage in the
earliest phases of care, recognition and monitoring of individual risk
factors, and therapeutic modulation of the inflammatory immune
response will probably constitute the next generation of therapy in
hemorrhagic shock. Further randomized controlled multicenter
clinical trials are needed that utilize standardized criteria for enrolling
patients, but existing ethical requirements must be maintained.
Introduction
Trauma is the leading cause of death worldwide in persons
aged between 5 and 44 years, and it has an impact in every
community regardless of demographics [1,2]. Up to 50% of
early deaths are due to massive hemorrhage, which is a major
contributor to the dilemmas associated with traumatic injury
and its care [3]. Studies have shown that hemorrhagic shock
is a predictor of poor outcome in the injured patient. Early
hypotension with hemorrhage in the field or at initial hospital
evaluation is associated with complications such as multiple
organ failure (MOF) and the development of secondary
infection such as pneumonia and sepsis [4-6].
The complex pathophysiology of hemorrhagic shock is
summarized in Figure 1. Briefly, the ‘shock syndrome’ during
massive bleeding reflects an imbalance between systemic
oxygen delivery and oxygen consumption [7,8]. Blood loss
leads sequentially to hemodynamic instability, coagulopathy,
decreased oxygen delivery, decreased tissue perfusion, and
cellular hypoxia [3]. Such alterations lay the foundations for
subsequent development of MOF, a systemic inflammatory
process that leads to dysfunction of different vital organs and
accounts for high mortality rates [9]. The pathogenesis of
organ injury secondary to hypovolemic insult is still
incompletely understood, but both experimental studies and
clinical observations suggest that leukocytes, in particular
macrophages, are activated by translocated bacterial endo-
toxin and hypoxia/reoxygenation [10,11]. Activated Kupffer
cells release pathologically active substances such as inflam-
matory cytokines, reactive oxygen species, and nitric oxide, all
of which may participate in the mechanisms of hemorrhagic
shock [11,12]. Moreover, increased free radical production
during hemorrhagic shock and resuscitation gives rise to
increased oxidative stress, which contributes to organ
damage [13,14]. In addition, data confirm that the biologic
precondition (namely sex, age, and genetic background) plays
an important role in the response to hemorrhage and therapy.
It is commonly accepted that bleeding control, damage
control surgery using interventional radiology, maintenance of
tissue oxygenation with fluid resuscitation, coagulation
support, and maintenance of normothermia represent basic
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support measures in hemorrhage care that can pre-empt or
rapidly reverse hypoxemia, hypovolemia, and the onset of
shock [15-17]. Regarding current resuscitation strategies,
management of hemorrhagic shock in the USA and Europe
relies heavily on blood replacement and fluid volume loading
to restore tissue perfusion [15-17]. Although resuscitation
strategies for severely injured patients who present with shock
have improved greatly, these transfusions are associated with
development of MOF, and increased intensive care unit (ICU)
admissions, ICU and hospital length of stay, and mortality
[18-21]. Although prevention of injury is plausible and
desirable, the complications of traditional treatment modalities
should be recognized and further clinical trials conducted to
evaluate potential new therapeutic strategies.
Biologic precondition: sex, age, and genetics
It was recently shown that the biologic precondition of
individuals (namely sex, age, and genetics) has a profound
impact on immune response after trauma/hemorrhage [22].
Although sex-specific differences in susceptibility to and
morbidity resulting from sepsis have been observed in several
epidemiologic and clinical studies [23-26], little attention has
been given to sex-specific differences in the immune
response to trauma and severe blood loss. Furthermore,
experimental studies investigating alterations in immune
functions after trauma have historically used male laboratory
animals. In this respect, a number of studies have
demonstrated diverse immune responses in male and female
mice after trauma/hemorrhage [27]. Higher plasma estradiol
and/or higher plasma prolactin levels might contribute to
enhanced immune response after hemorrhage in pro-estrus
females. Administration of estrogen in castrated male mice,
even with testosterone supplementation, improved the
depressed immune responses after trauma/hemorrhage [28].
Moreover, treatment of intact male mice with estradiol norma-
lized the depressed immune responses after trauma and
hemorrhage, and improved the survival rate after subsequent
sepsis [29]. A prospective study conducted in more than
4,000 trauma patients recently demonstrated that hormonally
active women tolerate trauma/shock better than men [30].
Figure 1
Illustration of the pathophysiological changes in hemorrhagic shock. DIC, disseminated intravascular coagulopathy; NO, nitric oxide.Page 3 of 13
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Dehydroepiandrosterone (DHEA) has also been reported to
have estrogenic effects [31]. Treatment of male mice with
DHEA after trauma and blood loss prevented immuno-
suppression and decreased susceptibility of those mice to
subsequent sepsis [32]. Because DHEA is used clinically as
a long-term immuno-enhancing drug, this hormone might
represent a useful therapy for preventing immunodepression
in surgical patients. Recently, DHEA was found to stimulate
the release of proinflammatory cytokines from human
peripheral blood mononuclear cells after major abdominal
surgery  in vitro [33]. A prospective clinical trial, however,
must be conducted to validate the immunoprotective effects
of DHEA in patients after severe blood loss. In addition to
female sex steroids, the lower levels of male hormones in
female animals as compared with males might also contribute
to the divergent immunoresponsiveness observed after injury
and blood loss. Depletion of testosterone by castration
before hemorrhage or by administration of flutamide after
hemorrhage and resuscitation normalized the depressed
immune responses and maintained cardiovascular function in
male animals [27]. Because flutamide is used clinically
without major side effects, this might represent a clinically
relevant therapeutic approach in trauma victims.
In addition, age must be taken into account when
extrapolating experimental results into clinics. This is because
recent studies have indicated that aged male and female
mice exhibit different sex-specific immune responses than do
young animals [34,35].
The availability of improved techniques for molecular diagnosis
has allowed investigation of the roles played by genetic
variations in the inflammatory responses to trauma/hemorrhage.
New diagnostic tools have revealed the importance of genetic
background on pathophysiological mechanisms and their
modulation after shock [36]. In this respect, clinical studies
revealed that IL-6-174G/C polymorphism is associated with
increased severity of post-traumatic systemic inflammatory
response syndrome [37], suggesting an adverse outcome in
those patients. Furthermore, it has been shown that the 1,082
IL-10 polymorphism is associated with acute respiratory failure
after major trauma [38]. In addition, specific genetic variations
in the mitochondrial DNA that influence energy production and
free radical generation appear to increase the risk for in-
hospital mortality after severe injury [39]. To date, genomics
findings in patients have only been used as prognostic factors,
and have not been used to direct therapy after hemorrhage.
Larger scale studies are needed to improve our understanding
of how genetic variability influences responses to post-
traumatic complications and pharmacotherapy.
In summary, the above-mentioned studies collectively
suggest that sex, age, and genetics reveal potential clinically
relevant therapeutic options. However, several promising
experimental approaches such as tumor necrosis factor
(TNF) antibody and others [9,40] have not been successful in
the clinical arena for the treatment of shock because of the
redundancy in the inflammatory pathways. Other pathways
and cytokines may activate and/or inhibit the system at the
same point, and different mediators may function as co-
determinants of the inflammatory system in parallel. Therefore,
modulating rather than neutralizing a cytokine is the desired
objective in the treatment of trauma victims. At present,
however, such strategies are in the early stages of
investigation. Furthermore, because of the complexity of
genetic patterns, it remains difficult to apply genetic
preconditions to develop individualized hemorrhage therapy.
Monitoring
In patients who have or have had hemorrhagic shock, heart
rate, urine output, capillary refill, systolic blood pressure, and
mental status represent the basic parameters that define
cardiovascular stability. Appropriate additional monitoring
primarily includes arterial pressure (via arterial catheter),
arterial hemoglobin oxygen saturation (via pulse oximetry),
and central venous pressure (via central venous line)
monitoring. Measurement of arterial blood gases with lactate
and base deficit determinations indicate the severity of shock,
and serial hemoglobin measurements allow assessment of
ongoing bleeding [15-17]. The goal is to return blood
pressure and heart rate to normal, and establish urine output
while maintaining central venous pressure in a moderate
range (8 to 15 mmHg) [41]. How specific those traditional
parameters are in the clinical arena and which values
represent the end-point that should be reached are still under
extensive discussion. In particular, restoration of vital signs to
normal while uncontrolled hemorrhage is ongoing may be
detrimental to the patient, causing volume overload and
rebleeding, and thus creating a vicious cycle of events.
Therefore, hypotensive resuscitation, whereby safe but
subnormal blood pressure is achieved, may represent a future
strategy to avoid the problems that result from use of
traditional resuscitation strategies [2,42].
Studies indicate that oxygen debt and lactate appear to play
important roles in defining the severity of hemorrhagic shock;
thus, normalizing these parameters might be appropriate
therapeutic end-points [41,43]. Currently, indirect measure-
ment techniques that reflect cellular oxygen utilization and
perfusion, either systemically (lactate and base deficit) or
locally (gastric intramucosal pH and microdialysis), are
primarily used [44]. Experimental and clinical studies have
indicated that evaluation of tissue perfusion with measure-
ment of cutaneous and transcutaneous partial oxygen tension
(PO2), skeletal muscle PO2, gastric tonometry, pH deter-
mination using fiberoptic technology, infrared spectroscopy,
and minimally invasive monitoring with measurement of
bladder mucosa pH and partial carbon dioxide tension (PCO2)
may represent new techniques for monitoring patients with
hemorrhagic shock [45-50]. However, at present these
technologies require the use of relatively complex or invasive
methodologies. Moreover, newer experimental results demon-
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muscle and subcutaneous pH, PO2, and PCO2 - as potential
surrogates of impaired tissue metabolism - vary among
tissues and according to the phase of hemorrhage or
resuscitation [51]. New bioimpedance technology to monitor
cardiac output has successfully been applied to direct trauma
resuscitation in the emergency department setting [52].
Buccal PCO2 measurement and high intensity focused
ultrasound also represent new and promising techniques;
they have proven to be practical and reliable measurements
in the diagnosis of circulatory failure states and to serve as
useful indicators of the severity of these states [53,54].
Although these techniques may move the end-points of
hemorrhagic shock to the organic, cellular, and subcellular
levels, large clinical studies are scarce. More precise tech-
niques for monitoring hemorrhagic shock are thus required,
which can be easily and repeatedly applied in the clinical
setting.
It is well known that shock initiates dysfunctional inflammation
that causes MOF. Resuscitation is a vital intervention that
decreases the severity of the shock insult, but current
strategies are not directed at modulating the immune
response; in fact, they may worsen it. Those parameters that
are routinely monitored in the clinical setting do not
adequately reflect the immune status of the patient (hyper-
inflammation versus immunoparalysis), which is important
when starting traditional and immunomodulatory therapies.
Proinflammatory cytokine levels correlate with prognosis; in
this respect, elevated levels of TNF-α, IL-1, and IL-6 in plasma
have been well described in both animal experiments [55-57]
and patient studies [58-62] after trauma and severe blood
loss. Measurement of soluble inflammatory parameters can
be routinely performed in many institutions. However, there
are several important limitations because determination of
soluble inflammatory mediators does not entirely reflect
cytokine tissue levels; they therefore may not represent a
good indicator for the extent of tissue inflammation and organ
damage. Furthermore, a single mediator may not be an
adequate indicator of the inflammatory response because of
the complexity of the underlying pathways. In this regard,
newer biotechnological methods may be employed to identify
immune cell surface markers (HLA-DR); expression of pro-
inflammatory and anti-inflammatory mediators at the immune
cell level (intracellular cytokine staining, cytokine secretion
assay) and cytokine gene expression via array technology
may demonstrate new tools for diagnosis and monitoring of
critically ill patients with bleeding [63-65]. Nonetheless, pro-
inflammatory cytokine levels might soon become important in
the management of trauma patients in the ICU. Knowledge of
the patient’s cytokine levels may yield some indicator of the
intracellular milieu and possibly provide insight into the cellular
changes taking place. This information might provide the
clinician with a better understanding of how to treat such a
critically ill trauma patient. However, the techniques require
refinement to allow rapid and online measurement of cytokines
before the full benefit of such information can be effectively
translated into better management of trauma patients.
Although various cytokine therapies in critically ill patients
have not yet yielded satisfactory results, the lack of beneficial
effect might be related to timing and dose of anticytokine
administered. It is our hypothesis that total blockade/
neutralization of cytokines will not be helpful to the host.
Rather, modulation of cytokine production/release by immune
cells (macrophages and T cells), leading to restoration of
cellular homeostasis, might be a better way to decrease the
susceptibility of trauma victims to subsequent sepsis and
infection. However, further basic research to investigate
inflammatory pathways and identify co-determinants will repre-
sent an inescapable prerequisite for progress in this area.
Resuscitation
For the past four decades, the standard approach to the
trauma victim who is hypotensive from presumed hemorrhage
has been to infuse large volumes of isotonic crystalloids as
early and as rapidly as possible [15-17,66]. The goals of this
treatment strategy are rapid restoration of intravascular
volume and vital signs, and maintenance of vital organ
perfusion. The most efficient solution for use in resuscitation
is still under debate. Lactated Ringer’s (LR) and normal
isotonic saline solution (NS) remain the most commonly used
isotonic fluids [16]. Although colloid solutions, including
hyperosmolar colloid and hypertonic electrolyte compounds,
have been approved for use as volume expanders, their
administration is still under debate in the USA and Europe
[16,17].
It is generally believed that LR is better than NS because it
provides a better buffer for metabolic acidosis, but
investigators have still not validated this hypothesis. Experi-
mental studies have revealed that resuscitation with NS in the
setting of massive hemorrhage requires significantly greater
volume and is associated with increased physiologic
derangements (for example, hyperchloremic acidosis and
dilutional coagulopathy) and higher mortality as compared
with LR [67,68]. In contrast, results from a recent preclinical
study [69] indicated increased endothelial dysfunction after
resuscitation with LR alone. Alternative crystalloid solutions
have also been developed (for instance, Ringer’s ethyl pyru-
vate) that exhibit anti-inflammatory properties [70], but a recent
experimental study [71] showed that resuscitation with
Ringer’s ethyl pyruvate was not associated with improved early
hemodynamics or tissue energetics as compared with LR.
The first prospective randomized controlled trials were
initiated during the mid-1970s to compare semisynthetic
colloid solutions (gelatins, dextrans, and hydroxyethyl
starches) as plasma volume expanders in critically ill patients,
with pulmonary dysfunction as the primary end-point because
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entity termed ‘shock lung’ [72-74]. However, the results of
the studies were not definitive because of differences in
study design, small numbers of patients included, hetero-
geneous populations, differences in resuscitation end-points,
and difficulties in defining pulmonary dysfunction. Nonethe-
less, if mortality is used as the end-point and the data are
subgrouped, then the use of crystalloids in trauma patients is
associated with improved survival [74]. Several additional
systematic reviews were conducted, but the large variation in
patient populations impeded clear interpretation. It was finally
concluded that because there was no evidence that one
colloid solution was safer than another, and because no
reduction in risk for death was evident in critically ill patients,
continued use of these agents in these patients could not be
justified outside the setting of randomized controlled trials
[74,75]. Although experimental results indicated that resus-
citation with LR and colloids have equivalent effects on
indices of inflammation in the lungs [76], reported data from
several studies conducted in critically ill patients have indica-
ted that use of colloid solutions has a significant impact on
hemorrhage, hemostasis, and inflammatory response [77-79].
Because human serum albumin (HSA) is responsible for 80%
of the colloid osmotic pressure of plasma, it may represent a
possible resuscitation fluid in hemorrhagic shock. However, a
meta-analysis of studies using albumin-containing fluids
revealed that their use is associated with a 1.68-fold increase
in the relative risk for death when compared with a crystalloid
solution [80]. This effect is related to an increased leakage of
albumin into the extravascular spaces, worsening the edema
that takes place during hypovolemia and exacerbating
respiratory and cardiac failure [81]; possible contamination of
the preparation with prion/viral components poses additional
risk to users. Nonetheless, in a large-scale clinical trial
conducted in Australia and New Zealand, in which 4%
albumin was compared with NS for intravascular fluid
resuscitation, no difference in mortality was reported [82].
Recombinant HSA may offer a new perspective, because
reported data indicate a high retention rate in circulating
blood and lower vascular permeability than with the native
HSA [81]; however, potential immunological alteration after
the use of recombinant HSA in critically ill patients must be
investigated.
The most recent studies of hemorrhagic shock and
resuscitation suggest that our current protocols are far from
ideal, and may in fact be harmful [41]. During the past
decade, several studies have investigated different strategies
in resuscitation. In the 1980s the first report of use of
hypertonic saline was published [83]. Small volume hyper-
tonic saline was shown to be as effective as large volume
crystalloids in expanding plasma volume; enhancing cardiac
output and microcirculation; limiting acute lung injury,
neutrophil activation, and red blood cell injury; and restoring
renal performance in animals with hemorrhagic shock
[84,85]. However, the increased microcirculation after
resuscitation with hypertonic saline in animals was associated
with increased bleeding, but mortality was model dependent
and the best survival was obtained when saline was given
with high-volume crystalloid [83]. A further experimental study
demonstrated enhanced resuscitation effects with a
combination of hypertonic saline and dextran [86]. Several
clinical studies followed, and a meta-analysis of those studies
[87] revealed that hypertonic saline is not better than the
current standard of care, namely isotonic fluids, but the
combination of hypertonic saline with dextran might be
superior. Trauma patients with combined head injury and
hemorrhagic shock profited the most because data showed
that resuscitation with this combination increased cerebral
perfusion, and decreased intracranial pressure and brain
edema. Therefore, hypertonic saline solutions have evolved
as an alternative to mannitol. However, caution is advised
with high osmolar loads because they carry increased risk for
potentially deleterious consequences of hypernatremia, or
they may induce osmotic blood-brain barrier disruption, with
possibly harmful extravasation of the hypertonic solution into
the brain tissue [88]. Moreover, a randomized controlled trial
[89] indicated that prehospital resuscitation with hypertonic
saline in patients with hypotension and severe traumatic brain
injury led to almost identical neurological function 6 months
after injury as in patients who received conventional fluids.
Nevertheless, investigation of the optimal resuscitation fluid is
an ongoing field of interest.
Other current experimental data indicate that titrated
hypertonic solutions combined with 10% hydroxyethyl starch
are superior to LR without increasing blood loss [90].
Moreover, the optimal fluid composition appears to play an
important role because a single bolus of 3% saline with 6%
dextran-70 was able to raise mean arterial pressure and
tissue oxygen saturation while attenuating post-traumatic
hypercoagulability in an animal model of uncontrolled
hemorrhagic shock [91]. Further benefit may result from the
combination of hypertonic saline and the immunoactive
phosphodiesterase inhibitor pentoxifylline [92]. Resuscitation
with this combination has been shown to prevent lung injury
and bacterial translocation, downregulate inducible nitric
oxide synthase, and decrease end-organ damage [93-95].
However, those resuscitation strategies must prove their
efficacy in the clinical arena, and therefore further randomized
clinical trials are needed. In this regard, two prehospital
intervention trials were recently successfully designed and
implemented to compare hypertonic saline resuscitation with
or without dextran versus conventional isotonic resuscitation
in patients with hypovolemic shock or traumatic brain injury
[96]. The results of these studies will hopefully advance and
improve the early care of severely injured patients.
Transfusion
Early administration of blood is one potential treatment to
decrease the need for massive crystalloid solution in
Available online http://ccforum.com/content/12/4/218
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blood and potential adverse effects make this option
logistically difficult and possibly harmful [15-17]. In addition,
potential infectious complications (hepatitis, HIV, and
bacterial contamination), immune suppression [97-99], and
metabolic complications (hyperkalemia, hypocalcemia, and
citrate toxicity) and risk for mistransfusion [100] are well
documented. Transfusion-related risks include possible
development of MOF, increased ICU admissions and length
of stay, increased hospital length of stay, and mortality
[18-21]. As a result, intensive investigations were conducted
to develop a new artificial oxygen carrier (Table 1).
Perfluorocarbons (PFCs) are an interesting development,
representing simply constructed molecules from cyclic or
straight-chain hydrocarbons with hydrogen atoms replaced
by halogens (fluorine or bromide), which are characterized by
a linear relationship between arterial PO2 and oxygen content
[101]. PFCs are insoluble in water and must be emulsified for
intravenous administration. The oxygen release from PFCs to
tissue is almost complete in the presence of a high PO2
gradient between arterial blood and tissue. However,
administration of PFCs is restricted to low dosages because
studies have indicated that PFC emulsion droplets are rapidly
taken up by the reticuloendothelial system and subsequently
cause immunosuppression [101,102]. Experimental studies
have demonstrated that use of PFCs allows the extension of
acute normovolemic anemia (hematocrit 21% to 8%) without
signs of impaired tissue oxygenation or compromised myo-
cardial contractility [103,104]. Clinical application of PFCs
has been shown to maintain gastrointestinal tissue
oxygenation at hemoglobin levels below 7 g/dl, to delay the
interval until transfusion of allogenic blood was required, and
to decrease the number of transfused red blood cell units in
patients undergoing cardiac and noncardiac surgery
[105-107]. However, enrollment in a phase III study
investigating administration of PFCs in cardiac surgical
patients was discontinued because of an increased rate of
neurological complications. A recent multicenter phase III
study conducted in patients undergoing noncardiac surgery
and suffering high-volume blood loss demonstrated an
increased incidence of postoperative ileus, in addition to
typical mild side effects (flu-like symptoms, fever, headache,
nausea, and myalgia) [101,107].
Hemoglobin-based oxygen carriers (HBOCs) for trauma
resuscitation may provide a workable compromise, because
their use in experimental studies of severe hemorrhagic shock
demonstrated stabilization of hemodynamic status and tissue
oxygenation, and decreased mortality [108-111]. Moreover,
the postischemic interactions between leukocytes and
endothelium were attenuated by infusion of human and
bovine HBOC [112-114]. Surprisingly, an interim analysis of
clinical application of the long-term favorite HBOC diaspirin-
crosslinked hemoglobin (HemAssist™; Baxter Healthcare,
Round Lake, IL, USA) for treatment of severe trauma-
hemorrhagic shock [115] demonstrated increased rates of
24-hour and 48-hour mortality; therefore, the trauma study
was discontinued. In contrast, pyridoxylated glutaraldehyde-
polymerized hemoglobin (PolyHeme™; Northfield Labs Inc.,
Evanston, IL, USA) proved to be an effective resuscitation
fluid in 171 patients suffering from massive hemorrhage
[116]. Although experimental studies indicated that adminis-
tration of HBOC-201 (polymerized bovine hemoglobin;
Hemopure™; Biopure Corp., Cambridge, MA, USA) in
hemorrhagic shock is effective and improved outcome, the
potential vasoconstrictive properties of all HBOCs must be
taken into account if their use is considered [117-120]. The
clinical impact is not yet fully understood, but possible
underlying mechanisms include scavenging of nitric oxide,
Critical Care    Vol 12 No 4 Angele et al.
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Table 1
Artificial oxygen carriers
Category Product Type MW (Daltons) Phase of testing
Perfluorocarbons Oxygent™ Perfluoroctylbromide 450 to 500 Up to clinical phase III, 
discontinued
Hemoglobin-based  HemAssist™ Diaspirin-crosslinked hemoglobin (human) 65,000 Up to clinical phase III, 
oxygen carrier discontinued
Hemopure™ Polymerized bovine hemoglobin (bovine) 250,000 Up to clinical phase III
Polyheme™ Pyridoxylated glutaraldehyde-polymerized  150,000 Up to clinical phase III
hemoglobin (human)
Hemospan™ Maleimide-activated polyethylene-glycol- 95,000 Up to clinical phase II, phase 
modified hemoglobin (human) III planned
Hemoglobin vesicles Oxygenix™ Hemoglobin containing liposomes (OXY-0301) Unpublished Experimental, up to phase I 
Presented are the physiochemical characteristics and state of clinical research on artificial oxygen carrier. The manufacturers are as follows:
Oxygent™, Alliance Pharmaceutical Corp., San Diego, CA, USA; HemAssist™, Baxter Healthcare, Round Lake, IL, USA; Hemopure™, Biopure
Corp., Cambridge, MA, USA; Polyheme™, Northfield Lab Inc., Evanston, IL, USA; Hemospan™, Sangart Inc., San Diego, CA, USA; and Oxygenix™,
Oxygenix Co. Ltd., Tokyo, Japan.augmented release of endothelin, and stimulation of endo-
thelin receptors and adrenoreceptors [117-120]. In this respect,
a nonvasoactive HBOC was recently developed (maleimide-
activated polyethylene-glycol-modified hemoglobin; Hemospan™)
and proven to provide sufficient tissue oxygenation at the
microcirculatory level in an experimental model of hemor-
rhagic shock [121]. Hemospan™ (Sangart Inc., San Diego,
CA, USA) has finished testing in phases I and II, and a phase
III prehospital trial is underway [122].
Another promising development representing hemoglobin
vesicles involves use of phospholipid vesicles (liposomes)
that encapsulate purified human hemoglobin. Because experi-
mental studies in hemorrhagic shock have shown that fluid
resuscitation with hemoglobin vesicles maintained systemic
oxygenation and did not induce either vasoconstriction or
activation of the immune system, their further investigation in
hemorrhagic shock is needed [123,124].
Vasoactive substances
The primary goal of treatment in hemorrhagic shock is prompt
restoration of tissue perfusion. However, this concept has
come under debate, particularly in uncontrolled and ad-
vanced hemorrhage [125]. In the initial phase of hemorrhagic
shock, vasopressors are widely used to maintain blood
pressure while resuscitation is ongoing. However, during the
late phase of hemorrhagic shock, replacement of fluids and
blood may become ineffective, even when supported by
traditional vasopressors such as norepinephrine, which
indicates a paralyzed vasculature [125].
Theorized mechanisms of vasomotor paralysis partly involve
tissue acidosis, hypoxia, and ATP depletion. The ATP-
sensitive potassium channels in particular represent an
important regulator of the vascular tone of arterioles, and thus
blood supply of most organs is regulated in part via these
channels [126,127]. However, if too many organs try to
obtain additional perfusion, which is simply not possible
during severe shock, then regional perfusion decreases and a
vicious shock cycle results. Adrenal insufficiency in
hemorrhagic shock may also represent a contributing factor
[128]. Most recently, vasopressin - a recognized endogenous
stress hormone - has been found to represent a potential
drug therapy that can prevent this vicious shock cycle.
Experimental studies demonstrated that vasopressin can
inhibit both ATP-sensitive potassium channels and nitric oxide
induced accumulation of cGMP [129]. In critically ill patients
such as those suffering out-of-hospital cardiac arrest or
septic shock, vasopressin has been identified to be highly
supportive [130,131]. Experimental studies conducted in
trauma and hemorrhagic shock have also indicated that
administration of vasopressin minimized fluid resuscitation
volume, improved cardiopulmonary parameters, led to a
markedly improved neurologic outcome if brain injury was
present, and improved survival [132-134]. Regarding
potential benefits in patients with hemorrhage, only case
reports are currently available, but a multicenter trial was
recently initiated [135]. A recent retrospective data analysis
revealed that caution should be exercised with vasopressor
treatment in hemorrhagic shock, because increased mortality
in blunt injured adults with hemorrhagic shock was observed
after use of vasopressors as compared with aggressive early
crystalloid resuscitation [136]. However, that study had
several limitations. Specifically, it was a secondary analysis,
and those patients who required early vasopressor treatment
were older, more severely injured, had worse initial shock
parameters, and required greater resuscitation after injury,
more invasive monitoring, and treatment in the ICU. There-
fore, further prospective randomized trials are needed to
address this issue adequately and identify potential
confounders.
In contrast, a newly identified vasodilatory peptide, namely
adrenomedullin, which is depressed after severe blood loss
because of downregulation of adrenomedullin binding protein
(AMBP)-1 [137], acts as a circulating hormone that elicits
various biologic activities in a paracrine and autocrine
manner. Human AMBP-1 has been shown to potentiate
adrenomedullin-induced vascular relaxation in the aorta under
normal and pathophysiological conditions [138]. Experi-
mental studies revealed that administration of adrenomedullin
in combination with AMBP-1 in hemorrhagic shock improved
cardiac performance and tissue perfusion, attenuated hepatic
and renal injury, prevented metabolic acidosis, down-
regulated proinflammatory cytokines, and reduced mortality
[137,139,140]. The beneficial effect of adrenomedullin/
AMBP-1 is associated with downregulation of endothelin-1,
which is normally upregulated in hemorrhagic shock [140].
However, clinical studies are necessary to evaluate the
precise underlying mechanisms and potential benefits of
adrenomedullin and its binding protein in traumatic injury and
hemorrhagic shock.
Coagulation support
Excessive hemorrhage is associated with coagulopathy,
which is proportional to the volume of blood loss [141].
Analysis of adult patients receiving more than 10 units of red
blood cells in a major trauma center identified acidosis (pH
<7.1), hypothermia (<34°C), Injury Severity Score above 25,
and systolic blood pressure below 70 mmHg as independent
risk factors for coagulopathy [142]. Nonetheless, coagulo-
pathy is generally multifactorial and additional contributing
factors include the following [143]: hemodilution, hypo-
volemia, hypothermia-associated platelet dysfunction, activa-
tion of the coagulation and fibrinolytic cascades, endothelial
cell damage leading to disseminated intravascular coagula-
tion, impaired hepatic synthesis of coagulation factors,
decreased clearance of activated factors, and release of
tissue factors into the circulation. In addition to rewarming,
coagulation factor replacement with fresh frozen plasma,
prothrombin complex concentrates, fibrinogen concentrates,
antifibrinolytics (tranexamic acid and ε-aminocaproic acid),
Available online http://ccforum.com/content/12/4/218
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management of bleeding [15,17,143].
An additional attractive candidate for maintaining coagulation
in hemorrhagic shock is recombinant factor VIIa (rFVIIa),
which has been approved for treatment of bleeding in
patients with hemophilia or vitamin K-antagonist therapy
[144]. Supraphysiological doses of rFVIIa bind to phospho-
lipid structures of activated platelets at the site of injury,
which may underlie the localized effects of this compound
[144]. In various animal models of hemorrhage, rFVIIa has
been shown to be an effective procoagulant adjunct for
controlling bleeding [145,146]. In addition to numerous
promising case studies that reported decreased mortality in
patients with severe trauma [144,147], only one randomized
clinical trial is available at present [148], which indicated
beneficial effects in the treatment of coagulopathic bleeding
after trauma. Although a recent systematic review of the
efficacy of rFVIIa in treatment of bleeding in patients without
hemophilia [149] revealed no difference in thromboembolic
events compared with placebo, there was also no difference
observed for death, total blood loss, and transfusion. Currently,
the rationale for using rFVIIa to treat massive bleeding is only as
an adjunct to the surgical control of bleeding if conventional
therapies have failed [150]. Although European and US
recommendations indicate that rFVIIa should be used in
massive bleeding [15,17], further randomized clinical trials are
warranted. A major randomized double-blind study is currently
being conducted in the USA, and the results will hopefully
verify the therapeutic benefits of rFVIIa in traumatic hemorrhage
as well as its potential adverse effects.
Future therapeutic approaches
Based on advances in the characterization of patho-
physiological mechanisms and identification of new
mediators after hemorrhagic shock, new therapeutic
strategies have been developed in clinically relevant animal
models. An incomplete selection of promising approaches is
presented in the following discussion. Clinical studies using
these agents must be conducted in the future to determine
their effectiveness in patients.
High-mobility group protein (HMGB)1 has been identified as
a late-acting mediator of lipopolyaccharide-induced or sepsis-
induced lethality in mice [151,152]. Moreover, HMGB1 is a
cytokine-like molecule that can promote TNF release from
mononuclear cells [153]. In addition, HMGB1 is actively
secreted by immunostimulated macrophages [154]. Similarly,
elevated plasma levels of HMGB1 were evident in patients
with trauma-induced hemorrhagic shock [155]. The above
studies collectively suggest that HMGB1 is involved in the
disease process after blood loss in patients and animals. In
view of this, anti-HMGB1 neutralizing antibodies used after
hemorrhagic shock and resuscitation in a clinically relevant
animal model demonstrate improved survival rates [155].
Moreover, anti-HMGB1 neutralizing antibodies decreased
bacterial translocation to mesenteric lymph nodes, associa-
ted with lower circulating levels of IL-6 and IL-10. Anti-
HMGB1 neutralizing antibodies warrant further evaluation as
a therapeutic option in patients who have suffered trauma
and hemorrhage.
α1 Acid glycoprotein (AAG), one of the acute phase proteins,
has been shown to protect endothelial barrier function and to
decrease leukocyte-endothelium interaction following adverse
circulatory conditions [156,157]. Endothelial cell dysfunction,
capillary leakage, and leukocyte accumulation play key roles
in initiating the pathophysiological mechanisms that become
active after trauma and hemorrhage. In view of this, studies
were conducted in which AAG was administered during
resuscitation after trauma and blood loss in rodents [158].
The results indicate that AAG reduced edema formation,
capillary leakage, and neutrophil accumulation after trauma
and blood loss. Although the precise underlying mechanisms
for the protective effects of AAG under those conditions are
unknown, the findings suggest that various mediators are
affected. Because there are many redundant pathways for
mediators, AAG appears to be a promising adjunct in the
clinical arena.
Additional pathways and mediators that might yield promising
therapeutic options are hydrogen sulfide and the use of its
blocker [159]. Additionally, blockade of reactive oxygen
species with hemigramicidin-TEMPO conjugate (a novel
mitochondria-targeted antioxidant) or 5-aminoisoquinolinone
(a poly-ADP-ribose synthase inhibitor) may provide cyto-
protection during hemorrhagic shock and after resuscitation
[160,161]. Moreover, complement depletion or inhibition
demonstrated beneficial effects in animal models of
hemorrhage, and therefore they represent an interesting novel
treatment option [162] in the clinical arena.
Studies have also shown that the use of 17β-estradiol
(estrogen) after trauma/hemorrhage in male or ovariectomized
female rodents improved cardiovascular and immunologic
functions and decreased mortality from subsequent sepsis
[22,27,163-170]. Because only a single dose of estrogen was
used, this was not a hormone replacement therapy and thus
should be considered as a safe and effective adjunct for
maintaining cardiovascular and immunologic responses
following low-flow conditions in male and female trauma
patients. Studies have also shown that flutamide (androgen
receptor antagonist) after trauma/hemorrhage in males
increased aromatase activity, increased estrogen levels,
upregulated estrogen receptors, and improved cell/organ
function under those conditions [171,172]. Additional studies
have shown that the use of DHEA, metoclopramide, prolactin,
or progesterone [172-174] as adjuncts to resuscitation after
trauma/hemorrhage also produced salutary effects on
cardiovascular and immunologic functions after trauma/
hemorrhage, and so their use in the clinical arena also appears
to be warranted [172-174].
Critical Care    Vol 12 No 4 Angele et al.
Page 8 of 13
(page number not for citation purposes)Conclusion
Hemorrhagic shock is a leading cause of death in trauma
patients worldwide. Despite improved resuscitation strategies
for severely injured patients who present in shock, these
transfusions are associated with development of MOF,
increased ICU admissions and length of stay, increased
hospital length of stay, and increased mortality. An important
contributing factor may be the marked suppression of cell-
mediated immunity after hemorrhage treated with adequate
fluid resuscitation, which is associated with an increased
susceptibility to subsequent sepsis. Other factors that may
profoundly influence outcomes after hemorrhage include age,
sex, nutritional status, socioeconomic background, and pre-
existing disease or infection.
Bleeding control, maintenance of tissue oxygenation with fluid
resuscitation, coagulation support, and maintaining normo-
thermia remain mainstays of therapy for patients with hemor-
rhagic shock. However, further benefits are anticipated from
new technologies that are being brought into clinical use,
especially hypertonic colloid saline, HBOCs, recombinant
factor VIIa, and less invasive early monitors. In addition,
promising results from experimental studies have demon-
strated that recombinant HSA as a plasma expander as well
as administration of vasopressin, adrenomedullin, estradiol,
metoclopramide, prolactin, flutamide, or DHEA to maintain
cardiac output, tissue perfusion and oxygenation may be
beneficial in hemorrhagic shock. Furthermore, prevention of
capillary leakage due to blockade of reactive oxygen
formation,  maintenance of endothelial barrier function, and
attenuation of the hyperinflammatory immunological response
are additional experimental approaches that are of therapeutic
interest in combating hemorrhage-associated complications.
Hemorrhagic shock can be rapidly fatal. It is self-evident that
prevention of injury is preferable and feasible, but control of
hemorrhage in the earliest phases of care, recognition and
monitoring of individual risk factors, and therapeutic
modulation of the inflammatory immune response may repre-
sent the next generation of care in hemorrhagic shock.
Further randomized controlled clinical trials are needed, but
existing ethical requirements must be maintained and
standardized criteria for enrolling comparable patient popula-
tions must be utilized.
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